Amycretin Evidence Guide
Zenagamtide now has published Phase 2 evidence for both oral and weekly subcutaneous formulations, making it one of the better-documented next-generation obesity candidates. Phase 3 development is underway, but no Phase 3 outcome data or regulatory approval exists, so approved semaglutide and tirzepatide remain ahead on decision-grade evidence.
Our Take
Zenagamtide now has published Phase 2 evidence for both oral and weekly subcutaneous formulations, making it one of the better-documented next-generation obesity candidates. Phase 3 development is underway, but no Phase 3 outcome data or regulatory approval exists, so approved semaglutide and tirzepatide remain ahead on decision-grade evidence.
- Evidence context
- Weight loss research, oral GLP-1/amylin dual agonism pharmacology, obesity treatment development
- Evidence grade
- Level B
- Confidence
- Moderate
- Reference context
- Reported research reference: Clinical-trial only; Phase 3 oral and subcutaneous dose protocols are under development
Benefits and Evidence
- Body Weight Reduction: Level B, includes human evidence - Novo Nordisk reported up to 14.6% mean weight loss at 36 weeks in a subcutaneous Phase 2 obesity study. Cross-trial comparisons with semaglutide, tirzepatide, or retatrutide are unreliable because duration, population, dose, and estimand differ.
- Glycemic Control: Level B, includes human evidence - At week 36, oral zenagamtide reduced HbA1c by about 0.9 to 1.4 percentage points and subcutaneous zenagamtide by about 0.9 to 1.7 points across dose groups in Phase 2 type 2 diabetes trials.
- Appetite Suppression: Level B, includes human evidence - Dual receptor agonism provides robust appetite suppression through complementary brainstem and hypothalamic pathways. Patient-reported hunger and food intake significantly reduced.
- Gastrointestinal Tolerability: Level B, includes human evidence - Nausea and vomiting are common side effects consistent with the GLP-1 and amylin agonist class. Dose titration strategy is being optimized to improve tolerability.
Side Effects and Warnings
- Nausea (most common)
- Vomiting
- Diarrhea
- Decreased appetite
- Constipation
- Investigational agent - not yet approved for clinical use
- Long-term safety and efficacy data not yet available
- GI side effects may limit tolerability at higher doses
Research Dosage References
- <strong>Subcutaneous injection</strong> - Dose-escalation (specific doses not yet disclosed) - Once weekly (anticipated) - Phase 2 trials ongoing. Dose-titration approach used to mitigate GI side effects. Oral formulation also in development.
- <strong>Oral</strong> - Under investigation - Once daily (anticipated) - Oral amycretin formulation in Phase 2 trials. If successful, would offer significant convenience advantage over injectable therapies.
Mechanism of Action
Amycretin provides dual appetite suppression through two complementary pathways: 1. GLP-1 receptor agonism: Activates GLP-1 receptors in the pancreas (enhancing glucose-dependent insulin secretion), hypothalamus (reducing appetite), and GI tract (slowing gastric emptying). 2. Amylin receptor agonism: Activates amylin receptors (calcitonin receptor + RAMP1/2/3 complex) in the area postrema and other brainstem regions, providing additional satiety signaling distinct from GLP-1 pathways. 3. Synergistic appetite suppression: The dual mechanism targets complementary neural circuits controlling food intake - GLP-1 primarily in hypothalamic and reward centers, amylin primarily in hindbrain satiety centers. 4. Glucose homeostasis: Both pathways contribute to improved glycemic control through enhanced insulin secretion, glucagon suppression, and delayed gastric emptying.
Legal Status
Investigational new drug. Novo Nordisk has advanced zenagamtide/amycretin into Phase 3 development for weight management in 2026; it is not approved by any regulatory authority and is not available outside clinical trials.
Primary Sources
- Efficacy and safety of once-daily oral zenagamtide in adults with type 2 diabetes: a phase 2 trial. Lancet, 2026.
- Efficacy and safety of once-weekly subcutaneous zenagamtide in type 2 diabetes: a phase 2 trial. Lancet, 2026.
- Subcutaneous zenagamtide Phase 2 obesity results and Phase 3 development update. Novo Nordisk News, 2026.
- Dual amylin and calcitonin receptor agonists: new therapeutic targets for obesity and metabolic disease. Br J Pharmacol, 2015.
Quick Answers
Where is the strongest evidence for Amycretin?
Zenagamtide now has published Phase 2 evidence for both oral and weekly subcutaneous formulations, making it one of the better-documented next-generation obesity candidates. Phase 3 development is underway, but no Phase 3 outcome data or regulatory approval exists, so approved semaglutide and tirzepatide remain ahead on decision-grade evidence. Evidence context: Weight loss research, oral GLP-1/amylin dual agonism pharmacology, obesity treatment development.
What are the main side effects of Amycretin?
Amycretin side effects and warning signals include Nausea (most common), Vomiting, Diarrhea, Decreased appetite, and Constipation.
What evidence level is Amycretin?
Amycretin is rated Level B; the listed research status is Phase 3.